{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0002861\nAge: 45\nGender: Female\nSample ID: P-0002861-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Primary\nTumor Purity: 20.0%\n=============\nDNA Variants:\nEGFR c.2573T>G (p.L858R) - in 62.00% of 2049 reads\nGRIN2A c.3170C>T (p.A1057V) - in 6.00% of 865 reads\nGRIN2A c.2632G>A (p.E878K) - in 5.00% of 559 reads\nNOTCH2 c.5542G>A (p.D1848N) - in 5.00% of 682 reads\nTP53 c.493C>T (p.Q165*) - in 10.00% of 616 reads\nCNA Data:\nEGFR - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"First-line treatment for metastatic or locally advanced NSCLC with EGFR mutations\",\n    \"Drug Name\": \"Osimertinib\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified; indicated for EGFR exon 21 p.L858R mutation\",\n    \"Genomic Features\": \"EGFR c.2573T>G (p.L858R)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf\"\n  }\n}"
}